Neural Cloud Retains Commission Wolf to Accelerate U.S. Commercial Expansion

Rhea-AI Summary

Neural Cloud, a wholly owned subsidiary of AI/ML Innovations (OTCQB:AIMLF), retained U.S. sales recruiter Commission Wolf on February 9, 2026 to build a U.S. commercial sales infrastructure for MaxYield™ and CardioYield™.

The agreement targets recruitment of 1099 independent sales representatives with cardiology relationships to support market entry as regulatory milestones are met and to accelerate pilot-to-commercial conversions.

• Engagement Supports Commercial Readiness Strategy for MaxYield^™ and CardioYield^™ in the United States

TORONTO, ON / ACCESS Newswire / February 10, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that its wholly owned subsidiary, Neural Cloud Solutions Inc. ("Neural Cloud"), has entered into an agreement on February 9^th, 2026 with Commission Wolf, a U.S.-based sales recruiting firm, to support the build-out of Neural Cloud's U.S. commercial sales infrastructure as the Company progresses on its regulatory milestones and commercialization of its MaxYield^™ and CardioYield^™ platforms.

Under the agreement, Commission Wolf will recruit a network of 1099 independent sales representatives with existing relationships across cardiology-focused healthcare settings, including OEM partners, cardiology clinics, diagnostic service providers, and other healthcare organizations.

The engagement reflects Neural Cloud's proactive approach to commercialization-ensuring that a scalable, experienced sales force is in place to support market entry once regulatory requirements are satisfied.

"Neural Cloud is building a compelling cardiac technology platform, and we see strong demand for solutions that improve diagnostic accuracy while reducing complexity and cost," said Peter Samargedlis, Owner of Commission Wolf. "Our role is to connect Neural Cloud with experienced, independent sales professionals who already have trusted relationships with OEMs, clinics, and diagnostic providers across the U.S. We're excited to help establish a scalable commercial foundation that supports long-term growth."

1099 sales representatives are independent contractors who typically bring established industry relationships, regional expertise, and immediate market access, enabling rapid and cost-efficient sales coverage across large geographic markets. This model allows Neural Cloud to scale customer acquisition while maintaining operational flexibility.

"As we move closer to regulatory milestones, it's critical that we are equally prepared on the commercial side," said Paul Duffy, Executive Chairman and CEO of AIML. "This engagement allows us to lay the groundwork for U.S. market entry by assembling a sales organization with deep cardiology experience and existing customer relationships."

Commission Wolf will lead a structured recruitment campaign to identify, screen, and introduce qualified independent sales representatives to Neural Cloud's management team. This initial recruitment phase is focused on assembling a core U.S. sales footprint capable of supporting early commercial deployments, pilot-to-commercial conversions, and strategic partnerships.

By investing early in sales readiness, Neural Cloud aims to shorten the time between regulatory clearance and revenue generation, while ensuring customers receive informed, clinically fluent engagement from representatives who understand cardiology workflows and decision-making.

Neural Cloud's MaxYield^™ and CardioYield^™ platforms are designed to support AI-driven ECG signal enhancement, automated waveform labeling, and high-throughput cardiac reporting-enabling faster, more accurate, and more accessible cardiac diagnostics.

About Commission Wolf

Commission Wolf is a specialized recruiting firm focused on building independent sales teams for healthcare, medical device, and health-technology companies. The firm recruits sales professionals with established industry relationships and connects them with companies seeking flexible, performance-driven commercial expansion models.

About AIML Innovations Inc.

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.

AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.

Contact:
Blake Fallis (778) 405-0882
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

SOURCE: AI/ML Innovations Inc.

View the original press release on ACCESS Newswire

FAQ

What did AIMLF announce about U.S. commercialization on February 9, 2026?

AIMLF engaged Commission Wolf to recruit independent sales reps for U.S. commercialization. According to the company, Commission Wolf will recruit a network of 1099 sales representatives with cardiology-focused relationships to prepare a scalable commercial footprint ahead of regulatory clearance.

How many sales representatives will Commission Wolf recruit for Neural Cloud (AIMLF)?

Commission Wolf will recruit a network of 1099 independent sales representatives numbering across targeted regions. According to the company, the recruitment focuses on reps with existing OEM, clinic, and diagnostic-provider relationships to enable rapid market access.

What roles will the 1099 sales representatives serve for Neural Cloud's MaxYield and CardioYield?

The 1099 reps will provide regional market access, customer introductions, and pilot-to-commercial support. According to the company, they will engage OEMs, cardiology clinics, and diagnostic service providers to support early deployments and strategic partnerships.

How does the Commission Wolf engagement affect AIMLF's timeline to revenue?

The engagement aims to shorten the interval between regulatory clearance and revenue generation. According to the company, early sales readiness is intended to accelerate customer acquisition and convert pilots to commercial contracts once regulatory milestones are satisfied.

What commercial capabilities do MaxYield and CardioYield offer for cardiology providers?

MaxYield and CardioYield offer AI-driven ECG signal enhancement, automated waveform labeling, and high-throughput cardiac reporting. According to the company, these platforms are designed to speed diagnostics, improve accuracy, and support clinical workflows for cardiology organizations.